Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498662 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL20983700 | 0.93 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL29130297 | 0.90 | ALDH1A1 (0.48) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL42368 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL29352062 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL28707482 | 0.86 | ALDH1A1 (0.57) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL1923934 | 0.85 | HPGD (0.53) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL10980056 | 0.84 | KMT2A (0.41) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL29356575 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL107907 | 0.83 | ALDH1A1 (0.39) | ALDH1A1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281628-A1 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | claimed |
| EP-4392087-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028082-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | WO | claimed |
| EP-2804631-B1 | SURROBODY CONJUGATES | I2 PHARMACEUTICALS INC (US) | 2021-03-17 | — | — | EP | claimed |
| EP-3275461-A1 | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE FIELD | Axon Neuroscience SE (CY) | 2018-01-31 | — | — | EP | claimed |
| US-9744241-B2 | Method for nucleic acid delivery using hyaluronic acid | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-29 | — | — | US | claimed |
| US-20140294752-A1 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID | Research & Business Foundation Sungkyunkwan University (KR) | 2014-10-02 | — | — | US | claimed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | claimed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | claimed |
| EP-1701968-A4 | IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME | WYETH CORP (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1206251-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2004-06-30 | — | — | EP | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| EP-1206251-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | claimed |
| WO-2000066090-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | claimed |
| EP-0473689-B1 | THROMBUS-TARGETED COMPLEXES OF PLASMINOGEN ACTIVATOR AND FIBRIN FRAGMENTS | UNIV TEMPLE (US) | 1994-12-14 | — | — | EP | claimed |
| EP-0308936-B1 | Antibody heteroconjugates for the killing of HIV-infected cells | BRISTOL MYERS SQUIBB CO (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0184701-B1 | A method for determining a ligand | HOECHST CELANESE CORP (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0440647-A1 | LABELED NUCLEIC ACID PROBE | BIOGEN, INC. (US) | 1991-08-14 | — | — | EP | claimed |
| WO-1989012110-A1 | LABELED NUCLEIC ACID PROBE | BIOGEN, INC. (US) | 1989-12-14 | — | — | WO | claimed |
| EP-0184701-A2 | A method for determining a ligand | HOECHST CELANESE CORPORATION (US) | 1986-06-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294752-A1 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID | CD44, DNASE1, HNRNPH3 | ALDH1A1 1523/4885KMT2A 2619/4885MAPT 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.